Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Five Prime Therapeutics Inc    FPRX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
21.19(c) 20.54(c) 21.72(c) 21.82(c) 21.96(c) Last
442 788 521 508 473 720 297 037 230 326 Volume
-2.62% -3.07% +5.74% +0.46% +0.64% Change
More quotes
Financials ($)
Sales 2017 44,3 M
EBIT 2017 -158 M
Net income 2017 -156 M
Finance 2017 305 M
Yield 2017 -
Sales 2018 77,6 M
EBIT 2018 -142 M
Net income 2018 -140 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 7,45x
Capi. / Sales2018 8,19x
Capitalization 635 M
More Financials
Company
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics.The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230.The FPA008 is an antibody that inhibits colony stimulating... 
More about the company
Surperformance© ratings of Five Prime Therapeutics In
Trading Rating : Investor Rating :
More Ratings
Latest news on FIVE PRIME THERAPEUTICS IN
01/09 FIVE PRIME THERAPEUTICS : Earns IND Milestone Payment Under Immune Checkpoint Pa..
01/08 Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint P..
01/03 FIVE PRIME THERAPEUTICS : Submits Investigational New Drug Application for Novel..
01/03 Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conf..
01/03 FIVE PRIME THERAPEUTICS : Begins Patient Dosing in Trial
01/02 Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase ..
2017 FIVE PRIME THERAPEUTICS : Zai gets Chinese rights to Five Prime's mAb
2017 FIVE PRIME THERAPEUTICS INC : Entry into a Material Definitive Agreement, Financ..
2017 ZAI LAB : Five Prime Therapeutics and Zai Lab Announce Exclusive License Agreeme..
2017 FIVE PRIME THERAPEUTICS : to Present at BMO Capital Markets Prescriptions for Su..
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/19Want the latest upgrades & downgrades for $FPRX $XLRN $VJET $ALLE $LEJU? .. 
01/18$FPRX - Five Prime Therapeutics #FPRX Rating Lowered to Sell at BidaskClub  
01/18Five Prime Therapeutics $FPRX Rating Lowered to Sell at BidaskClub  
01/12$FPRX - Five Prime Therapeutics #FPRX Getting Somewhat Positive Press Coverag.. 
01/12Five Prime Therapeutics $FPRX Getting Somewhat Positive Press Coverage, Repor.. 
More tweets
Qtime:100
News from SeekingAlpha
2017 FIVE PRIME THERAPEUTICS : Is This A High-Five Investment?
2017 WEEK IN REVIEW : Nearly $2 Billion Late-December Week For China Pharma Deals
2017 Five Prime Therapeutics (FPRX) Investor Presentation - Slideshow
2017 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2017 PREMARKET GAINERS AS OF 9 : 05 am
Chart FIVE PRIME THERAPEUTICS IN
Duration : Period :
Five Prime Therapeutics In Technical Analysis Chart | FPRX | US33830X1046 | 4-Traders
Technical analysis trends FIVE PRIME THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 63,1 $
Spread / Average Target 187%
EPS Revisions
Managers
NameTitle
Aron M. Knickerbocker President, Chief Executive Officer & Director
Lewis T. Williams Executive Chairman
Marc L. Belsky Chief Financial Officer & Senior Vice President
Luis Borges Senior Vice President-Research
Helen Collins Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
FIVE PRIME THERAPEUTICS INC-0.46%635
GILEAD SCIENCES14.10%105 754
VERTEX PHARMACEUTICALS4.76%39 951
REGENERON PHARMACEUTICALS-0.50%39 917
GENMAB10.50%11 762
EXELIXIS, INC.-9.57%8 284